Péan Noémie, Le Lay Aurelie, Brial Francois, Wasserscheid Jessica, Rouch Claude, Vincent Mylène, Myridakis Antonis, Hedjazi Lyamine, Dumas Marc-Emmanuel, Grundberg Elin, Lathrop Mark, Magnan Christophe, Dewar Ken, Gauguier Dominique
Inserm UMR 1124, Université de Paris, 45 rue des Saint-Pères, 75006, Paris, France.
McGill University and Genome Quebec Innovation Centre, 740 Doctor Penfield Avenue, Montreal, QC, H3A 0G1, Canada.
Diabetologia. 2020 Jun;63(6):1223-1235. doi: 10.1007/s00125-020-05122-7. Epub 2020 Mar 16.
AIMS/HYPOTHESIS: Drug and surgical-based therapies in type 2 diabetes are associated with altered gut microbiota architecture. Here we investigated the role of the gut microbiome in improved glucose homeostasis following bariatric surgery.
We carried out gut microbiome analyses in gastrectomised (by vertical sleeve gastrectomy [VSG]) rats of the Goto-Kakizaki (GK) non-obese model of spontaneously occurring type 2 diabetes, followed by physiological studies in the GK rat.
VSG in the GK rat led to permanent improvement of glucose tolerance associated with minor changes in the gut microbiome, mostly characterised by significant enrichment of caecal Prevotella copri. Gut microbiota enrichment with P. copri in GK rats through permissive antibiotic treatment, inoculation of gut microbiota isolated from gastrectomised GK rats, and direct inoculation of P. copri, resulted in significant improvement of glucose tolerance, independent of changes in body weight. Plasma bile acids were increased in GK rats following inoculation with P. copri and P. copri-enriched microbiota from VSG-treated rats; the inoculated GK rats then showed increased liver glycogen and upregulated expression of Fxr (also known as Nr1h4), Srebf1c, Chrebp (also known as Mlxipl) and Il10 and downregulated expression of Cyp7a1.
Our data underline the impact of intestinal P. copri on improved glucose homeostasis through enhanced bile acid metabolism and farnesoid X receptor (FXR) signalling, which may represent a promising opportunity for novel type 2 diabetes therapeutics.
目的/假设:2型糖尿病基于药物和手术的治疗与肠道微生物群结构改变有关。在此,我们研究了肠道微生物群在减重手术后改善葡萄糖稳态中的作用。
我们对患有自发性2型糖尿病的Goto-Kakizaki(GK)非肥胖模型的胃切除(通过垂直袖状胃切除术[VSG])大鼠进行了肠道微生物群分析,随后在GK大鼠中进行了生理学研究。
GK大鼠的VSG导致葡萄糖耐量的永久性改善,同时肠道微生物群发生微小变化,主要表现为盲肠普氏粪杆菌显著富集。通过允许性抗生素治疗、接种从胃切除的GK大鼠分离的肠道微生物群以及直接接种普氏粪杆菌,使GK大鼠的肠道微生物群富含普氏粪杆菌,结果导致葡萄糖耐量显著改善,且与体重变化无关。接种普氏粪杆菌和来自VSG治疗大鼠的富含普氏粪杆菌的微生物群后,GK大鼠的血浆胆汁酸增加;然后,接种的GK大鼠肝脏糖原增加,Fxr(也称为Nr1h4)、Srebf1c、Chrebp(也称为Mlxipl)和Il10的表达上调,Cyp7a1的表达下调。
我们的数据强调了肠道普氏粪杆菌通过增强胆汁酸代谢和法尼醇X受体(FXR)信号传导对改善葡萄糖稳态的影响,这可能为新型2型糖尿病治疗提供一个有前景的机会。